6-MAPDB
6-MAPDB is the N-methyl homolog of 6-APDB and the positional isomer of 5-MAPDB, an obscure benzofuran entactogen with essentially no human data. By analogy it is expected to produce MDMA-like emotional effects with a serotonergic bias, while carrying the neurotoxicity, hyperthermia, and serotonin-syndrome concerns of the class.
01 Overview
6-MAPDB rounds out the benzofuran entactogen series alongside 6-APB, 6-APDB, and 5-MAPDB. N-methylation of 6-APDB is expected to shift the profile toward MDMA-like effects.
No formal human pharmacology or toxicology exists. As a serotonin releaser it carries theoretical neurotoxicity and serotonin-syndrome risk, and benzofurans specifically raise 5-HT2B cardiovascular concerns. Likely covered by benzofuran, analog, or psychoactive-substances legislation.
02 Mechanism
N-methylated benzofuran serotonin-preferring releaser at monoamine transporters, predicted to give MDMA-like entactogenic effects.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Light | 50–90 mg | Oral | Estimated; potency poorly defined |
| Common | 90–150 mg | Oral | Estimated common range, high uncertainty |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Entactogenic effectsExpected MDMA-like emotional openness by analogy; direct reports are scarce. | Presumed moderate | Unconfirmed | |
| Serotonergic sedationPredicted serotonergic bias with modest stimulation. | Mild | Unconfirmed |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Serotonin syndromeTheoretical serious risk from serotonin release, especially in combination. | Life-threatening | Rare, elevated with serotonergic drugs | Unconfirmed | |
| Cardiovascular strainBenzofurans carry 5-HT2B agonism and cardiovascular load concerns. | Moderate | Common (predicted) | Unconfirmed | |
| HyperthermiaOverheating risk shared with the MDMA class. | Severe | Uncommon | Unconfirmed |